drugset / Trial / NCT06731933
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
Phase 2
Recruiting
16 enrolled
Stanford University
Epidermolysis Bullosa Research Partnership · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The study objective is to see if BVEC induced C7 expression in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin following Squamous cell carcinoma (SCC) excision will normalize the invasive tumor microenvironment and reduce tumor recurrence. Prevention of SCC's in the RDEB subjects will increase their life span.
Timeline
- Start
- 2025-03-28
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BVEC | Unknown | — | — |